Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05220722
Title Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors TriSalus Life Sciences, Inc.
Indications

hepatocellular carcinoma

intrahepatic cholangiocarcinoma

Therapies

Pembrolizumab + SD-101

Ipilimumab + Nivolumab + SD-101

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.